Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GRF6019 in severe Alzheimer's disease
NCT03765762Phase 2Completed
- Sponsor
- Alkahest, Inc.
- Start
- Jan 2019
- Primary completion
- Dec 2019
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of GRF6019 in Alzheimer's disease (AD), sponsored by Alkahest, Inc.. Started Jan 2019; status: completed.
02
Drugs
GRF6019
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT03765762.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03765762.